Table 5. Secondary Endpoints.

	Placebo (n=8,696)	Vitamin E alone (n=8,737)	Selenium alone (n=8,752)	Vitamin E + selenium (n=8,702)
Colorectal Cancer	75	85	74	93
Hazard ratio (99% CI)		1.09 (0.72, 1.64)	0.96 (0.63, 1.46)	1.21 (0.81, 1.81)
p-value		p=0.60	p=0.79	p=0.22
Lung Cancer	92	104	94	104
Hazard ratio (99% CI)		1.11 (0.76, 1.61)	1.02 (0.70, 1.50)	1.11 (0.76, 1.62)
p-value		p=0.49	p=0.89	p=0.48
All other primary cancers (excludes prostate, includes colorectal and lung)	579	570	557	594
Hazard ratio (99% CI)		0.97 (0.83, 1.14)	0.96 (0.83, 1.13)	1.02 (0.88, 1.19)
p-value		p=0.65	p=0.54	p=0.74
All cancers (including prostate)	1108	1190	1132	1149
Hazard ratio (99% CI)		1.07 (0.96, 1.19)	1.02 (0.92, 1.14)	1.02 (0.92, 1.14)
p-value		p=0.13	p=0.59	p=0.60
Deaths (all cause)	564	571	551	542
Hazard ratio (99% CI)		1.01 (0.86, 1.17)	0.98 (0.84, 1.14)	0.96 (0.82, 1.12)
p-value		p=.91	p=.67	p=.47
October 23, 2008†
Diabetes*	669	700	724	660
Relative Risk (99% CI)		1.04 (0.90 – 1.18)	1.07 (0.94 – 1.22)	0.97 (0.86 – 1.11)
p-value		p = 0.47	p = 0.16	p = 0.61
July 5, 2011
Diabetes*	869	918	913	875
Relative Risk (99% CI)		1.05 (0.93 – 1.17)	1.04 (0.93 – 1.17)	0.99 (0.89 – 1.12)
p-value		p = 0.29	p = 0.34	p = 0.91
Cardiovascular events, grade 4 or higher**	969	909	939	943
Hazard Ratio (99% CI)		0.93 (0.83,1.05)	0.97 (0.86,1.09)	0.97 (0.86,1.09)
p-value		p = 0.11	p = 0.45	p = 0.51

^†Date of data freeze for initial publication

^*Prevalent cases at baseline and men who never submitted a form with a diabetes assessment are excluded from the analysis.

^**Time to first reported cardiovascular event, cardiovascular procedure (e.g., CABG), or hemorrhagic stroke, all men. Cardiovascular endpoints were not centrally adjudicated.